RayzeBio, Inc. Common Stock
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RYZB research report →
Company
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company’s lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs).
- CEO
- Kenneth Song
- IPO
- 2023
- Employees
- 88
- HQ
- DE, US
Price Chart
Valuation
- Market Cap
- $3.75B
- P/E
- -35.73
- P/S
- 0.00
- P/B
- -22.02
- EV/EBITDA
- -51.45
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 82.72%
- ROIC
- -22.86%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-68,600,000 · -132.98%
- EPS
- $-1.75 · -139.73%
- Op Income
- $-72,120,000
- FCF YoY
- -65.51%
Performance & Tape
- 52W High
- $62.51
- 52W Low
- $17.95
- 50D MA
- $55.78
- 200D MA
- $36.72
- Beta
- 3.79
- Avg Volume
- 745.49K
Get TickerSpark's AI analysis on RYZB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 26, 24 | VIKING GLOBAL INVESTORS LP | other | 1,743,556 |
| Sep 19, 23 | Redmile Group, LLC | other | 498,510 |
| Sep 19, 23 | Redmile Group, LLC | other | 494,687 |
| Sep 19, 23 | Redmile Group, LLC | other | 864,509 |
| Sep 19, 23 | Redmile Group, LLC | other | 432,254 |
| Sep 19, 23 | Redmile Group, LLC | other | 498,510 |
| Sep 19, 23 | Redmile Group, LLC | other | 864,509 |
| Sep 19, 23 | venBio Global Strategic Fund III, L.P. | other | 247,343 |
| Sep 19, 23 | venBio Global Strategic Fund III, L.P. | other | 1,123,862 |
| Sep 19, 23 | venBio Global Strategic Fund III, L.P. | other | 3,786,957 |
Our RYZB Coverage
We haven't published any research on RYZB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RYZB Report →